explore -WSS

explore

author：comprehensive 2025-09-28 01:40:02 - browse：7787

Sterile capsules for injection line up in a dispensing line — politics coverage from STAT — Adobe

WASHINGTON — The Senate Finance Committee has drafted a bipartisan bill to mitigate drug shortages by rewarding hospitals for business practices that ensure an adequate supply of drugs.

Drug shortages have been a persistent problem for years, and they’re worse than ever, according to a recent report by the American Society of Health-System Pharmacists. Shortages are primarily a problem for hospitals and doctors who regularly administer drugs, including oncologists who have been running out of common chemo drugs. Generic injectables account for 67% of shortages, and more than half of drugs in short supply cost less than $1 per unit, according to the Finance Committee.

Hospitals band together to negotiate drug prices by hiring group purchasing organizations. The biggest three GPOs are estimated to control about 90% of the market for drugs that hospitals buy. Finance Chair Ron Wyden (D-Ore.) said those GPOs can drive prices down so low that manufacturers stop making certain drugs or can’t afford to maintain their facilities, which then leads to manufacturing interruptions. Drugmakers also say GPOs can also be fickle, switching from one manufacturer to another over small savings, leaving drugmakers without the certainty they need to commit to making large volumes of product.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： New weight loss drugs work. But how can they best be used?

WSS

Stroke deaths set to near 10 million globally by 2050

The biotech scorecard for Q1: 17 stock

Why age limits for politicians are a terrible idea

GSK Flovent asthma inhalers replaced by authorized generics

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

U.K. sequencing study surfaces new findings about tumor DNA

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

In age of alternative facts, a scholarly course on calling out crap

J&J to buy cancer drug developer Ambrx Biopharma

DIEP, the 'gold standard' of breast reconstruction, is under threat

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Medical records are filled with copy

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Feng Zhang, Grail founder join forces on new gene editing startup

Alkermes shareholders re

3 medical device trends to watch in 2024

explore

AI can decode, harness the power of the humane immune system

GSK Flovent asthma inhalers replaced by authorized generics

VC firm General Catalyst wants to buy a health system

A Q&A with the global head of Boehringer Ingelheim's innovation unit

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Federal weight loss drug coverage is 30 years out of date

focus

focus

hotspot

entertainment